FIT Biotech Ltd. Report issue

For profit Phase 2
Founded: Tampere Finland (1995)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
2017
NCT02972450
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

gtu-multhiv b vaccine (1 trial)

mvatg17401 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2